keyword
Keywords Principles and protocols for i...

Principles and protocols for intravenous fluid therapy

https://read.qxmd.com/read/33001413/prevention-of-hypomagnesemia-in-critically-ill-patients-with-acute-kidney-injury-on-continuous-kidney-replacement-therapy-the-role-of-early-supplementation-and-close-monitoring
#1
REVIEW
Francesca Di Mario, Giuseppe Regolisti, Paolo Greco, Caterina Maccari, Eleonora Superchi, Santo Morabito, Valentina Pistolesi, Enrico Fiaccadori
Hypomagnesemia is a common electrolyte disorder in critically ill patients and is associated with increased morbidity and mortality risk. Many clinical conditions may contribute to hypomagnesemia through different pathogenetic mechanisms. In patients with acute kidney injury (AKI) the need for continuous or prolonged intermittent kidney replacement therapy (CKRT and PIKRT, respectively) may further add to other causes of hypomagnesemia, especially when regional citrate anticoagulation (RCA) is used. The basic principle of RCA is chelation of ionized calcium by citrate within the extracorporeal circuit, thus blocking the coagulation cascade...
August 2021: Journal of Nephrology
https://read.qxmd.com/read/30648673/cardiac-output-monitoring-technology-and-choice
#2
REVIEW
Jeff Kobe, Nitasha Mishra, Virendra K Arya, Waiel Al-Moustadi, Wayne Nates, Bhupesh Kumar
The accurate quantification of cardiac output (CO) is given vital importance in modern medical practice, especially in high-risk surgical and critically ill patients. CO monitoring together with perioperative protocols to guide intravenous fluid therapy and inotropic support with the aim of improving CO and oxygen delivery has shown to improve perioperative outcomes in high-risk surgical patients. Understanding of the underlying principles of CO measuring devices helps in knowing the limitations of their use and allows more effective and safer utilization...
2019: Annals of Cardiac Anaesthesia
https://read.qxmd.com/read/23531379/when-enough-is-enough-how-the-decision-was-made-to-stop-the-feast-trial-data-and-safety-monitoring-in-an-african-trial-of-fluid-expansion-as-supportive-therapy-feast-for-critically-ill-children
#3
RANDOMIZED CONTROLLED TRIAL
Jim Todd, Robert S Heyderman, Philippa Musoke, Tim Peto
In resource-rich countries, bolus fluid expansion is routinely used for the treatment of poor perfusion and shock, but is less commonly used in many African settings. Controversial results from the recently completed FEAST (Fluid Expansion As Supportive Therapy) trial in African children have raised questions about the use of intravenous bolus fluid for the treatment of shock. Prior to the start of the trial, the Independent data monitoring committee (IDMC) developed stopping rules for the proof of benefit that bolus fluid resuscitation would bring...
March 26, 2013: Trials
https://read.qxmd.com/read/23361625/surviving-sepsis-campaign-international-guidelines-for-management-of-severe-sepsis-and-septic-shock-2012
#4
JOURNAL ARTICLE
R P Dellinger, Mitchell M Levy, Andrew Rhodes, Djillali Annane, Herwig Gerlach, Steven M Opal, Jonathan E Sevransky, Charles L Sprung, Ivor S Douglas, Roman Jaeschke, Tiffany M Osborn, Mark E Nunnally, Sean R Townsend, Konrad Reinhart, Ruth M Kleinpell, Derek C Angus, Clifford S Deutschman, Flavia R Machado, Gordon D Rubenfeld, Steven Webb, Richard J Beale, Jean-Louis Vincent, Rui Moreno
OBJECTIVE: To provide an update to the "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock," last published in 2008. DESIGN: A consensus committee of 68 international experts representing 30 international organizations was convened. Nominal groups were assembled at key international meetings (for those committee members attending the conference). A formal conflict of interest policy was developed at the onset of the process and enforced throughout...
February 2013: Intensive Care Medicine
https://read.qxmd.com/read/23353941/surviving-sepsis-campaign-international-guidelines-for-management-of-severe-sepsis-and-septic-shock-2012
#5
JOURNAL ARTICLE
R Phillip Dellinger, Mitchell M Levy, Andrew Rhodes, Djillali Annane, Herwig Gerlach, Steven M Opal, Jonathan E Sevransky, Charles L Sprung, Ivor S Douglas, Roman Jaeschke, Tiffany M Osborn, Mark E Nunnally, Sean R Townsend, Konrad Reinhart, Ruth M Kleinpell, Derek C Angus, Clifford S Deutschman, Flavia R Machado, Gordon D Rubenfeld, Steven A Webb, Richard J Beale, Jean-Louis Vincent, Rui Moreno
OBJECTIVE: To provide an update to the "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock," last published in 2008. DESIGN: A consensus committee of 68 international experts representing 30 international organizations was convened. Nominal groups were assembled at key international meetings (for those committee members attending the conference). A formal conflict of interest policy was developed at the onset of the process and enforced throughout...
February 2013: Critical Care Medicine
https://read.qxmd.com/read/11889475/diagnosis-and-management-of-increased-intracranial-pressure
#6
REVIEW
L J Dennis, S A Mayer
Increased intracranial pressure (ICP) is a pathological state common to a variety of neurological diseases, all of which are characterized by the addition of volume to the skull contents. Elevated ICP may lead to brain damage or death by two principle mechanisms: 1) global hypoxic-ischemic injury, as a consequence of reduced cerebral perfusion pressure (CPP) and cerebral blood flow; and 2) mechanical distortion and compression of brain tissue as a result of intracranial mass effect and ICP compartmentalization...
June 2001: Neurology India
https://read.qxmd.com/read/8683249/granulocyte-macrophage-colony-stimulating-factor-associated-with-induction-treatment-of-acute-myelogenous-leukemia-a-randomized-trial-by-the-european-organization-for-research-and-treatment-of-cancer-leukemia-cooperative-group
#7
RANDOMIZED CONTROLLED TRIAL
R Zittoun, S Suciu, F Mandelli, T de Witte, J Thaler, P Stryckmans, M Hayat, M Peetermans, M Cadiou, G Solbu, M C Petti, R Willemze
PURPOSE: To assess the value of granulocyte-macrophage colony-stimulating factor (GM-CSF) for induction treatment of acute myeloid leukemia (AML), both for priming of leukemic cells and for acceleration of hematopoietic recovery. PATIENTS AND METHODS: GM-CSF was administered 5 micrograms/kg/d by continuous intravenous (i.v.) infusion during induction therapy with daunorubicin (DNR) (days 1 to 3) and cytarabine (ARA-C) (days 1 to 7). A total of 102 patients were randomized onto four arms, as follows: (1) GM-CSF 24 hours before and during chemotherapy (arm +/-); (2) GM-CSF after chemotherapy until day 28 or recovery of polymorphonuclear leukocytes (PMNs) (arm -/+);(3) GM-CSF before, during, and after chemotherapy (arm +/+); or (4) no GM-CSF (arm -/-)...
July 1996: Journal of Clinical Oncology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.